Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Contribution of early administration of GH to the regeneration and beneficial remodeling of the left ventricle in patients with acute myocardial infarction [Contribucion de la administracion precoz de GH a la regeneracion y remodelado favorable del miocardio ventricular izquierdo en pacientes con infarto agudo de miocardio]

Trial Profile

Contribution of early administration of GH to the regeneration and beneficial remodeling of the left ventricle in patients with acute myocardial infarction [Contribucion de la administracion precoz de GH a la regeneracion y remodelado favorable del miocardio ventricular izquierdo en pacientes con infarto agudo de miocardio]

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatropin (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms REGENERA

Most Recent Events

  • 02 Apr 2012 Planned End Date changed to 12 Aug 2011.
  • 28 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top